Study of Presepsin Levels in Ascites Fluid to Predict Outcomes in Adults With Chronic Liver Failure

What this Trial Is About

Researchers are studying the predictive value of presepsin levels in ascites fluid among patients newly admitted with chronic liver failure. The study focuses on understanding whether presepsin, a fragment of the CD14 receptor involved in detecting bacterial components and triggering inflammation, can help predict outcomes in these patients. Previous studies suggested presepsin in blood may aid early infection diagnosis and mortality prediction in liver cirrhosis, but this study evaluates presepsin directly in ascites fluid. Participants will undergo a diagnostic procedure called paracentesis to collect ascites fluid, where presepsin levels will be measured. This observational study involves patients with chronic liver failure and ascites who meet technical requirements for safe paracentesis. No experimental treatments are given instead, presepsin levels are monitored to assess their relationship with patient outcomes. During the study, participants will be followed for six months to observe mortality and the occurrence of infections, including spontaneous bacterial peritonitis and hepatic encephalopathy. Researchers will collect clinical data and monitor health status regularly to evaluate how presepsin levels in ascites correlate with these outcomes. The study aims to improve prognostic tools for people living with chronic liver failure and ascites.

Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure